Indication
Malignant Melanoma
6 clinical trials
9 products
Product
IMM-1-104 MonotherapyClinical trial
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-01
Product
IMM-1-104Clinical trial
A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic MutationsStatus: Recruiting, Estimated PCD: 2027-06-01
Product
IMM-6-415Clinical trial
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Product
BCD-100Product
BCD-217Product
PlaceboClinical trial
A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaStatus: Completed, Estimated PCD: 2020-08-03
Product
Talimogene laherparepvecClinical trial
PD-1 Monoclonal Antibody With Recombinant Human Adenovirus Type 5 Injection for the Treatment of Advanced Malignant Melanoma Patients Who Has Failed Immunotherapy: an Exploratory Single-arm StudyStatus: , Estimated PCD: 2023-08-01